<DOC>
	<DOCNO>NCT00004215</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Colony-stimulating factor leridistim filgrastim increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Randomized phase II trial compare effectiveness leridistim filgrastim reduce side effect old patient receive cytarabine daunorubicin acute myeloid leukemia .</brief_summary>
	<brief_title>Leridistim Compared With Filgrastim Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose hematopoietically active dose leridistim administer induction chemotherapy old patient acute myeloid leukemia . II . Determine effect leridistim duration grade IV neutropenia induction course patient . III . Determine safety tolerability leridistim patient . IV . Compare effect leridistim v filgrastim ( G-CSF ) duration thrombocytopenia , incidence infection , need IV antibiotic patient . V. Compare effect leridistim v G-CSF number day platelet and/or red blood cell transfusion patient . OUTLINE : This dose escalation study leridistim randomize , open label , multicenter study . Patients randomize one two treatment arm . All patient receive induction chemotherapy consist daunorubicin IV 15-30 minute day 1-3 cytarabine IV continuously day 1-7 . Patients achieve aplasia one induction course may receive second course . Dose Escalation Phase : Patients receive leridistim subcutaneously ( SQ ) every day begin day 11-14 continue 42 day blood count recover . Cohorts 6 patient receive escalate dos leridistim maximum tolerate dose ( MTD ) hematopoietically active dose ( HAD ) determine . The MTD define dose prior dose level least 2 dose limit toxicity occur different patient . Consolidation Phase : Patients receive consolidation chemotherapy consist cytarabine IV 1 hour every 12 hour ( patient 70 year ) every 24 hour ( patient 70 year ) day 1-6 . Beginning 24-48 hour completion consolidation chemotherapy , patient receive leridistim . Randomized Phase : Eligible patient receive induction consolidation chemotherapy outline . Then patient randomize one two treatment . Arm I : Patients receive leridistim SQ every day 42 day blood count recover . Arm II : Patients receive filgrastim ( G-CSF ) SQ daily 42 day blood count recover . Patients follow day 30 6 12 month . PROJECTED ACCRUAL : A total 86 patient ( 36 phase I 50 phase II ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Induction phase : Cytologically prove de novo acute myeloid leukemia ( M3 ) Eligible receive cytarabine daunorubicin Circulating blast count great 75,000/mL ( hydroxyurea leukapheresis allow decrease blast count ) No blast transformation chronic myelogenous leukemia No myelodysplastic syndrome antecedent hematologic disorder longer 6 month Post Induction Phase : Severe bone marrow aplasia ( le 5 % blast le 10 % cellularity ) No persistent leukemia 2 induction course PATIENT CHARACTERISTICS : Age : 55 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No significant cardiac disease No cardiac arrhythmia No uncontrolled hypertension No recent myocardial infarction ischemia Other : No uncontrolled metabolic condition would preclude study No psychiatric condition would preclude study HIV negative Hepatitis B surface antigen negative No known hypersensitivity corticosteroid , E. coli protein , interleukin3 , SC55494 , SC68420 , leridistim , milodistim , filgrastim ( GCSF ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interleukin3 , milodistim , SC55494 , SC68420 , leridistim No prior peripheral blood stem cell bone marrow transplantation No concurrent epoetin alfa interleukin11 Chemotherapy : See Disease Characteristics No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : At least 2 week since prior surgery ( except catheter placement biopsy ) Other : At least 3 week since prior investigational drug No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>anemia</keyword>
	<keyword>neutropenia</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>